To include your compound in the COVID-19 Resource Center, submit it here.

TWi's AC-201 meets diabetes endpoint

TWi Biotechnology Inc. (Taipei, Taiwan) said oral AC-201 met the primary

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE